pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRISPR Therapeutics AG ($CRSP) · news · pharmadog
← back to CRISPR Therapeutics AG
News mentioning $CRSP
18
stories
3d
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
biospace
4d
Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicines
biospace
4d
Big-name investors pour $100M into DNA therapeutics developer Seawolf
biopharma dive
7d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
7d
This week in charts: Brain drugs are back on venture capitalists’ minds
biopharma dive
7d
Marrow extracts $120M series B to advance preclinical blood disease therapy
fiercebiotech
8d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
10d
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
biopharma dive
10d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
10d
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
fiercebiotech
18d
Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
biospace
Oct 20, 26
Most new drugs are still too costly at launch, ICER says
biopharma dive
Oct 15, 26
Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
fiercebiotech
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Aug 28, 26
#ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
endpoints
Aug 24, 26
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
endpoints
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat